After delays, Novavax Covid vaccine is on track for full FDA approval

Rejoice, fellow vaccine enthusiasts—it looks like there's good news on the horizon for Novavax, everyone's favorite scrappy, highly effective, Matrix-M adjuvanted, protein-based, non-mRNA COVID-19 vaccine, which also has the fewest side effects, to boot. The company announced yesterday that, after some delays that spurred patients and consumers to double down on their advocacy efforts, the COVID-19 Novavax vaccine looks to be on track to move from emergency authorization to full approval from the Food and Drug Administration—which means Novavax will be able to provide the vaccine indefinitely. — Read the rest

The post After delays, Novavax Covid vaccine is on track for full FDA approval appeared first on Boing Boing.